专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100255085A1 Progesterone Solutions for Increased Bioavailability 有权
标题翻译：孕激素提高生物利用度的解决方案
公开(公告)号：US20100255085A1
公开(公告)日：2010-10-07
申请号：US12752629
申请日：2010-04-01
申请人： Zhi Liu , Saujanya L. Gosangari , Dana S. Toops , Aqeel Fatmi
发明人： Zhi Liu , Saujanya L. Gosangari , Dana S. Toops , Aqeel Fatmi
IPC分类号： A61K9/48 , A61K31/57 , A61P5/34
CPC分类号： A61K9/4858 , A61K31/57 , A61K47/12 , A61K47/14
摘要： Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
摘要翻译：本文描述了用于疏水性药物（例如孕酮）的填充材料及其制备和使用方法。填充材料含有溶解在一种或多种脂肪酸中的疏水性药物。疏水性药物的浓度通常为填充材料重量的约7％至约50％。一种或多种脂肪酸的浓度为载体重量的约60％至约95％。制剂还含有一种有机酸和一种或多种药学上可接受的醇和一种或多种药学上可接受的中，长链脂肪酸的一，二或三酯的一种或两种。填充材料可以被包封在硬或软胶囊中。与悬浮在油中的微粉化孕酮相比，本文所述的制剂具有更高的溶解速率和更快的溶解出现，因此应该具有增加的体内生物利用度。

2. 发明授权

US09011908B2 Progesterone solutions for increased bioavailability 有权
标题翻译：黄体酮提高生物利用度的解决方案
公开(公告)号：US09011908B2
公开(公告)日：2015-04-21
申请号：US12752629
申请日：2010-04-01
申请人： Zhi Liu , Saujanya L. Gosangari , Dana S. Toops , Aqeel Fatmi
发明人： Zhi Liu , Saujanya L. Gosangari , Dana S. Toops , Aqeel Fatmi
IPC分类号： A61P5/34 , A61K9/48 , A61K31/57 , A61K47/12 , A61K47/14
CPC分类号： A61K9/4858 , A61K31/57 , A61K47/12 , A61K47/14
摘要： Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
摘要翻译：本文描述了用于疏水性药物（例如孕酮）的填充材料及其制备和使用方法。填充材料含有溶解在一种或多种脂肪酸中的疏水性药物。疏水性药物的浓度通常为填充材料重量的约7％至约50％。一种或多种脂肪酸的浓度为载体重量的约60％至约95％。制剂还含有一种有机酸和一种或多种药学上可接受的醇和一种或多种药学上可接受的中，长链脂肪酸的一，二或三酯的一种或两种。填充材料可以被包封在硬或软胶囊中。与悬浮在油中的微粉化孕酮相比，本文所述的制剂具有更高的溶解速率和更快的溶解出现，因此应该具有增加的体内生物利用度。

3. 发明授权

US08309107B2 Stable solutions of orlistat for pharmaceutical dosage forms 有权
标题翻译：用于药物剂型的奥利司他的稳定溶液
公开(公告)号：US08309107B2
公开(公告)日：2012-11-13
申请号：US12574215
申请日：2009-10-06
申请人： Zhi Liu , Dana S. Toops , Aqeel A. Fatmi
发明人： Zhi Liu , Dana S. Toops , Aqeel A. Fatmi
IPC分类号： A61K9/00 , A61K9/48 , A61K31/365 , A61K31/355 , A61K31/375
CPC分类号： A61K9/4858
摘要： Liquid orlistat-containing fill materials suitable for encapsulating in hard or soft capsules are described herein. The fill material contains orlistat dissolved in one or more medium chain triglycerides or medium chain partial triglycerides, one or more citrate esters, and combinations thereof. The fill material can also contain one or more pharmaceutically acceptable excipients. In one embodiment, the fill material is substantially free of surfactants. The fill material can be encapsulated in hard or soft, gelatin or non-gelatin capsules. The capsules may be coated to modify release of orlistat from the capsule. Alternatively, the fill material can be encapsulated in an enteric capsule, wherein the enteric polymer is a component of the capsule shell, rather than a coating over the capsule shell. The fill materials are stable at elevated temperatures over an extended period of time and allow for high loadings of orlistat (e.g., 20% w/w or higher).
摘要翻译：本文描述了适用于包封在硬胶囊或软胶囊中的含有液体奥利司他的填充材料。填充材料含有溶解在一种或多种中链甘油三酯或中链部分甘油三酸酯中的奥利司他，一种或多种柠檬酸酯及其组合。填充材料还可以含有一种或多种药学上可接受的赋形剂。在一个实施方案中，填充材料基本上不含表面活性剂。填充材料可以包封在硬或软的明胶或非明胶胶囊中。胶囊可以被涂覆以改变从胶囊释放奥利司他。或者，填充材料可以包封在肠溶胶囊中，其中肠溶性聚合物是胶囊壳的组分，而不是胶囊壳上的涂层。填充材料在高温下在延长的时间内是稳定的并且允许高负荷的奥利司他（例如，20％w / w或更高）。

4. 发明申请

US20100087520A1 STABLE SOLUTIONS OF ORLISTAT FOR PHARMACEUTICAL DOSAGE FORMS 有权
标题翻译：用于药物剂型的ORLISTAT的稳定解决方案
公开(公告)号：US20100087520A1
公开(公告)日：2010-04-08
申请号：US12574215
申请日：2009-10-06
申请人： Zhi Liu , Dana S. Toops , Aqeel A. Fatmi
发明人： Zhi Liu , Dana S. Toops , Aqeel A. Fatmi
IPC分类号： A61K31/365 , A61K31/355 , A61K31/375
CPC分类号： A61K9/4858
摘要： Liquid orlistat-containing fill materials suitable for encapsulating in hard or soft capsules are described herein. The fill material contains orlistat dissolved in one or more medium chain triglycerides or medium chain partial triglycerides, one or more citrate esters, and combinations thereof. The fill material can also contain one or more pharmaceutically acceptable excipients. In one embodiment, the fill material is substantially free of surfactants. The fill material can be encapsulated in hard or soft, gelatin or non-gelatin capsules. The capsules may be coated to modify release of orlistat from the capsule. Alternatively, the fill material can be encapsulated in an enteric capsule, wherein the enteric polymer is a component of the capsule shell, rather than a coating over the capsule shell. The fill materials are stable at elevated temperatures over an extended period of time and allow for high loadings of orlistat (e.g., 20% w/w or higher).
摘要翻译：本文描述了适用于包封在硬胶囊或软胶囊中的含有液体奥利司他的填充材料。填充材料含有溶解在一种或多种中链甘油三酯或中链部分甘油三酸酯中的奥利司他，一种或多种柠檬酸酯及其组合。填充材料还可以含有一种或多种药学上可接受的赋形剂。在一个实施方案中，填充材料基本上不含表面活性剂。填充材料可以包封在硬或软的明胶或非明胶胶囊中。胶囊可以被涂覆以改变从胶囊释放奥利司他。或者，填充材料可以包封在肠溶胶囊中，其中肠溶性聚合物是胶囊壳的组分，而不是胶囊壳上的涂层。填充材料在高温下在延长的时间内是稳定的并且允许高负荷的奥利司他（例如，20％w / w或更高）。

5. 发明授权

US5837870A Process to prepare oxazolidinones 失效
标题翻译：制备恶唑烷酮的方法
公开(公告)号：US5837870A
公开(公告)日：1998-11-17
申请号：US828923
申请日：1997-03-28
申请人： Bruce A. Pearlman , William R. Perrault , Michael R. Barbachyn , Peter R. Manninen , Dana S. Toops , David J. Houser , Thomas J. Fleck
发明人： Bruce A. Pearlman , William R. Perrault , Michael R. Barbachyn , Peter R. Manninen , Dana S. Toops , David J. Houser , Thomas J. Fleck
IPC分类号： C07D263/20 , C07D263/24 , C07D295/00 , C07D413/04 , C07D413/10 , C07D487/04 , C07D521/00 , C07D249/16
CPC分类号： C07D487/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D263/20 , C07D263/24 , C07D413/04 , C07D413/10
摘要： The present invention includes processes for producing 5-hydroxymethyl substituted oxazolidinone alcohols (III) from carbamates (IIA) or a trifluoroacetamide (IIB) using a dihydroxy compound (I) or glycidol (IV) starting material and for the transformation of the hydroxymethyl substituted oxazolidinone alcohols (III) to the corresponding amino compounds, 5-aminomethyl substituted oxazolidinone amines (VII) which are acylated to form commercially useful antibacterial 5-acylamidomethyl substituted oxazolidinone (VIII).
摘要翻译：本发明包括使用二羟基化合物（I）或缩水甘油（IV）起始物从氨基甲酸酯（IIA）或三氟乙酰胺（IIB）制备5-羟甲基取代的恶唑烷酮醇（III）和用于羟甲基取代的恶唑烷酮醇（III）与相应的氨基化合物，5-氨基甲基取代的恶唑烷酮胺（VII），其被酰化形成商业上有用的抗菌5-酰氨基甲基取代的恶唑烷酮（VIII）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式